Cargando…

Dabigatran Plasma Measurement to Guide the Management of Acute Bleeding and Thrombotic Complications

Oral anticoagulant therapy is recommended for the prevention and treatment of venous thromboembolism and to prevent stroke in non-valvular atrial fibrillation. Until a few years ago, vitamin K antagonists were the only drugs available, but direct oral anticoagulants have recently been introduced int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tala, Maurizio, Paoletti, Oriana, Dellanoce, Claudia, Morandini, Rossella, Valtulina, Carlo, Sessa, Maria, Testa, Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SMC Media Srl 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346816/ https://www.ncbi.nlm.nih.gov/pubmed/30756068 http://dx.doi.org/10.12890/2018_000947

Ejemplares similares

Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants
por: Testa, Sophie, et al.
Publicado: (2019)

Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study
por: Giorgi-Pierfranceschi, Matteo, et al.
Publicado: (2020)

Management of dabigatran-induced bleeding: expert statement
por: Fries, Dietmar, et al.
Publicado: (2013)

Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma
por: Kaptein, Fleur H. J., et al.
Publicado: (2022)

Use of a specific antidote to dabigatran (idarucizumab) reduces blood loss and mortality in dabigatran-induced and trauma-induced bleeding in pigs
por: Honickel, M, et al.
Publicado: (2014)

Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban
por: Charlton, Blake, et al.
Publicado: (2018)

Dabigatran: Clinical correlation of drug and its dose with risk of stroke and bleeding
por: Shaji, Anitta, et al.
Publicado: (2023)

Heyde’s Syndrome Complicating Management in a Patient With High Bleeding and Thrombotic Risks
por: Ahmed, Talha, et al.
Publicado: (2020)

Safety and timing of resuming dabigatran after major gastrointestinal bleeding reversed by idarucizumab
por: Riario Sforza, Gian Galeazzo, et al.
Publicado: (2018)

Risk factors and prevention of dabigatran‐related gastrointestinal bleeding in patients with atrial fibrillation
por: Nantsupawat, Teerapat, et al.
Publicado: (2017)

Evaluation of the Bleeding Intensity of Patients Anticoagulated with Warfarin or Dabigatran Undergoing Dental Procedures
por: Andrade, Marcus Vinicius Santos, et al.
Publicado: (2018)

Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
por: Gendron, Nicolas, et al.
Publicado: (2017)

Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register
por: Palareti, Gualtiero, et al.
Publicado: (2020)

Determination of Dabigatran Concentration in Human Plasma and Breast Milk
por: Sidgwick, F., et al.
Publicado: (2021)

Bleeding and thrombotic complications associated with anticoagulation prior to lung transplantation: a case series
por: Shepherd, Hailey M., et al.
Publicado: (2022)

Bleeding and thrombotic complications in patients with severe COVID‐19: A prospective observational study
por: Helmy, Mina A., et al.
Publicado: (2022)

Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO‐Kyoto Thrombotic and Bleeding Risk Scores
por: Natsuaki, Masahiro, et al.
Publicado: (2018)

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
por: Kim, Jong-Min, et al.
Publicado: (2022)

Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study
por: van der Veen, Lucia, et al.
Publicado: (2021)

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
por: Abraham, Neena S, et al.
Publicado: (2015)

Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed(,,)
por: Milling, Truman J., et al.
Publicado: (2016)

Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed
por: Milling, Truman J., et al.
Publicado: (2016)

Idarucizumab reverses dabigatran-induced anticoagulation in treatment of gastric bleeding: A case report
por: Jia, Yu, et al.
Publicado: (2022)

The Dabigatran debate
por: Kaba, Riyaz A, et al.
Publicado: (2014)

Risk of Gastrointestinal Bleeding Among Dabigatran Users – A Self Controlled Case Series Analysis
por: Tang, Wenze, et al.
Publicado: (2017)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Major bleeding events in octagenarians associated with drug interactions between dabigatran and P-gp inhibitors
por: Bernier, Marjorie, et al.
Publicado: (2019)

Serpins in Hemostasis as Therapeutic Targets for Bleeding or Thrombotic Disorders
por: Bianchini, Elsa P., et al.
Publicado: (2021)

Bleeding and Thrombotic Issues during Extracorporeal Membrane Oxygenation
por: Ranucci, Marco, et al.
Publicado: (2022)

The Discovery of Dabigatran Etexilate
por: van Ryn, Joanne, et al.
Publicado: (2013)

Dabigatran and apolipoprotein B
por: ten Cate, Hugo
Publicado: (2016)

Characterization of the complications associated with plasma exchange for thrombotic thrombocytopaenic purpura and related thrombotic microangiopathic anaemias: a single institution experience
por: McGuckin, S, et al.
Publicado: (2014)

Peripartum cardiomyopathy and thrombotic complications
por: Aksu, Ugur, et al.
Publicado: (2019)

Thrombotic complications of COVID-19
por: Avila, Jacob, et al.
Publicado: (2021)

Recurrent and Drastic Increase in Dabigatran Levels May Be Induced by Therapeutic Plasma Exchange
por: Pflug, Marc A., et al.
Publicado: (2020)

Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients
por: Testa, Sophie, et al.
Publicado: (2020)

Survival analysis of patients taking dabigatran who consulted an emergency department for acute bleeding: a first alarm
por: Arlet, OA, et al.
Publicado: (2013)

Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review
por: Milling, Truman J., et al.
Publicado: (2017)

Association Between the Change in Total Bilirubin and Risk of Bleeding Among Patients With Nonvalvular Atrial Fibrillation Taking Dabigatran
por: Xiong, Yurong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hd21vuu7gba29rudtig6peb29i